Home
PLRZ
PLRZ News

Latest POLYRIZON LTD (PLRZ) News on May 16, 2025

GlobeNewswire

3 days ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

MT Newswires

13 days ago

Top Midday Gainers

MT Newswires

13 days ago

Polyrizon Shares Surge After Dropping Reverse Stock Split Plan

GlobeNewswire

21 days ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

MT Newswires

a month ago

Polyrizon Gets Nasdaq Noncompliance Notice Over Minimum Bid Price Rule

GlobeNewswire

a month ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

GlobeNewswire

a month ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

GlobeNewswire

a month ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

GlobeNewswire

a month ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

GlobeNewswire

2 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

GlobeNewswire

2 months ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Psychedelic: atai Life Sciences, NRx report quarterly results

TipRanks

2 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

GlobeNewswire

2 months ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

MT Newswires

2 months ago

Polyrizon Signs Letter of Intent With Biotech Firm for Use of Its Intranasal Drug Delivery Platform

GlobeNewswire

2 months ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

GlobeNewswire

2 months ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

GlobeNewswire

2 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

GlobeNewswire

2 months ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

GlobeNewswire

4 months ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

GlobeNewswire

4 months ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

GlobeNewswire

5 months ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

GlobeNewswire

5 months ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

GlobeNewswire

5 months ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

GlobeNewswire

5 months ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

GlobeNewswire

5 months ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

ACCESSWIRE

7 months ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

GlobeNewswire

7 months ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Share on Social Networks: